Operationalizing Innovative Biomarkers to Support Evolving Therapeutic and Diagnostic Landscape for Neurodegenerative Diseases

Globally, more than 20 million people are diagnosed with Alzheimer’s disease. Researchers have made tremendous progress in understanding Alzheimer’s disease pathology, resulting in a consensus on the biological definition of the disease. Novel blood-based biomarkers, such as pTau217 and Aβ 42/40, have also emerged.

Now, with the approval of Eisai and Biogen’s Leqembi^TM and Lilly’s Kisunla^TM, therapeutic development efforts by biopharma have been reinvigorated, and diagnostics are now enabled by available therapies. The shifting dynamics of therapeutic development in dementia and neurodegenerative disease treatment requires an understanding not only of the diseases themselves but also an understanding of the patient care continuum from diagnosis to treatment.

To fully realize the benefits of promising emerging biomarkers like Aβ 42/40 or pTau217, the global ecosystem for bringing these biomarkers into practical use in drug development and diagnostic environments must be considered.

In this webinar, the expert speakers discuss novel biomarkers relevant to Alzheimer’s disease and other neurodegenerative diseases and explore various platforms that support these biomarkers across a range of regulatory environments. They will bring real-life examples featuring innovative solutions and ecosystem partnerships that must be considered with global Alzheimer’s disease clinical trial approaches.

Join this webinar to learn more about how a holistic understanding of the disease pathology of Alzheimer’s disease, Lewy body dementia and more — in both diagnostics and drug development — can drive accelerated therapies to patients in need.

Speakers

Dr. Magali Dupont, Staff Scientist, Immunology, Labcorp

Dr. Magali Dupont holds a PhD in Immunology from the Institut Pasteur in Paris and joined the immunology department at Labcorp Central Laboratory Services in 2021. In her role, she oversees validation work performed at the central laboratory in Geneva, Switzerland, addresses scientific operational challenges and investigates new biomarkers and methodologies to ensure high-quality scientific delivery.

With the increased focus on biomarkers for neurodegenerative diseases, Dr. Dupont has led the validation and operationalization of several assays and platforms to support clinical trials, as well as acquired valuable functional experience, allowing Labcorp to offer multiple approaches to support neurobiomarker testing.

Message Presenter

Robert Martone, Scientific Discipline Director, Neurology, Labcorp

Robert Martone is a Research Scientist with deep expertise in neurodegeneration, neuro-oncology, biomarkers and drug discovery. He investigated hereditary neuropathies and the molecular biology of the blood-brain barrier at Columbia University and subsequently managed a portfolio of drug discovery programs at Wyeth Neuroscience targeting Alzheimer’s and Parkinson’s disease.

He served as the Neuroscience Therapeutic Area Lead for the Former Covance Biomarker Center of Excellence. More recently, he served as Director of Pre-Clinical Research at Cognition Therapeutics and later supported late-stage biomarker and diagnostics efforts at Biogen. He is currently the Scientific Discipline Director for Neurology at the Labcorp Biomarker Solution Center.

Message Presenter